DALLAS / Sep 30, 2025 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) will release its third quarter 2025 results before the market opens on Tuesday, October 28, 2025, to be followed by a conference call at 9:30 a.m. CT (10:30 a.m. Eastern Time).
A live webcast and audio archive of the call may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
| Last Trade: | US$206.49 |
| Daily Change: | -2.13 -1.02 |
| Daily Volume: | 1,098,498 |
| Market Cap: | US$18.240B |
October 28, 2025 July 22, 2025 April 29, 2025 February 12, 2025 October 29, 2024 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load